# Dabrafenib With Trametinib in the Adjuvant Treatment of High-risk BRAF V600 Mutation-positive Melanoma (COMBI-AD).

> **NCT01682083** · PHASE3 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 870 (actual)

## Conditions studied

- Melanoma

## Interventions

- **DRUG:** Dabrafenib
- **DRUG:** Trametinib
- **DRUG:** Placebos

## Key facts

- **NCT ID:** NCT01682083
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-01-08
- **Primary completion:** 2017-06-30
- **Final completion:** 2023-07-31
- **Target enrollment:** 870 (ACTUAL)
- **Last updated:** 2026-04-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01682083

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01682083, "Dabrafenib With Trametinib in the Adjuvant Treatment of High-risk BRAF V600 Mutation-positive Melanoma (COMBI-AD).". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT01682083. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*